Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recursion Pharmaceuticals's Beginning Cash Position for the quarter that ended in Jun. 2026 was MXN11,606.7 Mil.
Recursion Pharmaceuticals's quarterly Beginning Cash Position
increased
from Dec. 2025 (MXN12,012.4 Mil) to Mar. 2026 (MXN13,595.2 Mil) but then
declined
from Mar. 2026 (MXN13,595.2 Mil) to Jun. 2026 (MXN11,606.7 Mil).
Recursion Pharmaceuticals's annual Beginning Cash Position
declined
from Dec. 2023 (MXN9,490.5 Mil) to Dec. 2024 (MXN8,372.0 Mil) but then
increased
from Dec. 2024 (MXN8,372.0 Mil) to Dec. 2025 (MXN10,857.9 Mil).
Recursion Pharmaceuticals Beginning Cash Position Related Terms
Recursion Pharmaceuticals Beginning Cash Position Historical Data
* Premium members only.
The historical data trend for Recursion Pharmaceuticals's Beginning Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recursion Pharmaceuticals Beginning Cash Position Chart
What does a Beginning Cash Position of MXN11,606.7 Mil mean?
Recursion Pharmaceuticals (MEX:RXRX) has a Beginning Cash Position of MXN11,606.7 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Recursion Pharmaceuticals and its competitors.
Is Recursion Pharmaceuticals' Beginning Cash Position too high?
Recursion Pharmaceuticals' current Beginning Cash Position is MXN11,606.7 Mil. Overall, Recursion Pharmaceuticals has a GF Score™ of 43/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Beginning Cash Position compare to INVA and TSHA?
Recursion Pharmaceuticals' Beginning Cash Position of MXN11,606.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current Beginning Cash Position is MXN11,606.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (MEX:RXRX) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN50.45, compared to a current price of MXN59.39 — trading 17.7% above its estimated fair value. The current Beginning Cash Position is MXN11,606.7 Mil. Recursion Pharmaceuticals' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Recursion Pharmaceuticals (MEX:RXRX), the current Beginning Cash Position is MXN11,606.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recursion Pharmaceuticals (MEX:RXRX) Overvalued in 2026?
Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN59.39 is trading 17.7% above its estimated GF Value™ of MXN50.45.
GuruFocus considers Recursion Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for MEX:RXRX:
Beginning Cash Position: MXN11,606.7 Mil
GF Value™: MXN50.45 vs. price of MXN59.39 (17.7% above fair value)
No single metric tells the full story. See the MEX:RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
43GF Score
Get the complete analysis for MEX:RXRX
Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RXRX has been successfully added to your 
